Clinical Efficacy of Probiotic Bifidobacterium longum for the Treatment of Symptoms of Japanese Cedar Pollen Allergy in Subjects Evaluated in an Environmental Exposure Unit

この論文にアクセスする

この論文をさがす

著者

    • XIAO Jin-zhong
    • Food Research and Development Laboratory, Morinaga Milk Industry Co., Ltd.
    • KONDO Shizuki
    • Food Research and Development Laboratory, Morinaga Milk Industry Co., Ltd.
    • MIYAJI Kazuhiro
    • Food Research and Development Laboratory, Morinaga Milk Industry Co., Ltd.
    • ENOMOTO Keisuke
    • Department of Otolaryngology and Sensory Organ Surgery, Osaka University Medical School
    • SAKODA Takema
    • Department of Otolaryngology, Japanese Red Cross Society Wakayama Medical Center
    • IWATSUKI Keiji
    • Food Research and Development Laboratory, Morinaga Milk Industry Co., Ltd.
    • ENOMOTO Tadao
    • Department of Otolaryngology, Japanese Red Cross Society Wakayama Medical Center

抄録

<b>Background:</b> Japanese cedar pollinosis (JCPsis) affects nearly one in six Japanese. Oral administration of <i>Bifidobacterium longum</i> BB536 has been shown to be effective in relieving JCPsis symptoms during the pollen season.<br> <b>Methods:</b> This double- two-way crossover study was designed to evaluate the efficacy of BB536 on reducing symptoms in JCPsis patients exposed to Japanese cedar pollen (JCP) in an environmental exposure unit (EEU) outside of the normal JCP season. After a 1-week run-in period, subjects (<i>n</i> = 24) were randomly allocated to receive BB536 powder (approximately 5 × 10<sup>10</sup>) or placebo twice a day for 4 weeks. After a 2-week washout period, subjects were crossed over to another 4 weeks of intake. At the end of each intake period, subjects received controlled JCP exposure for 4 hours in the EEU. Symptoms were self-rated 30 minutes before and every 30 minutes during the exposures. From the first day of exposure through the next 5 successive days, participants self-rated their delayed symptoms and medication uses. Blood samples were taken before the exposures. The mean JCP levels for exposures were 6500 to 7000grains/m<sup>3</sup> air.<br> <b>Results:</b> In comparison with placebo, BB536 intake significantly reduced the ocular symptom scores during JCP exposures. Evaluating delayed symptoms after exposures indicated that scores for disruption of normal activities were significantly lower in the BB536 group compared with the placebo group. Prevalence of medication use was markedly reduced by BB536 intake.<br> <b>Conclusions:</b> These results suggest the potential beneficial effect of BB536 in relieving symptoms of JCP allergy<br>

収録刊行物

  • Allergology international : official journal of the Japanese Society of Allergology  

    Allergology international : official journal of the Japanese Society of Allergology 56(1), 67-75, 2007-03-01 

    Japanese Society of Allergology

参考文献:  25件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  6件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018873904
  • NII書誌ID(NCID)
    AA11091750
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13238930
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ